Abstract:Background: To develop and validate a radiomic signature for the prediction of lymph node metastasis (LNM) in T1 colorectal cancer (CRC) patients by utilizing common, non-invasive, clinical imaging data. With this signature, patients with T1 CRC at a lower-risk of LNM may avoid extensive radical surgical treatments required in high-risk cases.Methods: This retrospective analysis included 559 T1 CRC patients enrolled at three hospitals. Key radiomic features were extracted from CT images and T2w-MR images using a coarse-to-fine feature selection strategy. These features were used to generate three radiomic signatures based on CT, MR and combined (CT&MR) imaging data. The performance of these radiomic signatures were compared within the primary and external validation cohorts. Furthermore, their prediction performance and clinical usefulness were measured and compared with those of a clinical information-based model.Findings: The radiomic signature combining CT and MR images achieved AUCs of 0.872 (95% CI, 0.770-0.974) in the primary cohort and 0.812 (95% CI, 0.709-0.915) in validation cohort 1, which were significantly better than those of other prediction models. More importantly, the signature achieved high negative predictive values (95.5% in the primary cohort and 97.9% in the validation cohort 1). The decision curve analysis demonstrated the clinical usefulness of this signature.Interpretation: The study suggests that the radiomic signature can accurately predict LNM in cases of T1 CRC. Furthermore, combining CT and MR images can achieve better performance. Specifically, the radiomic signature can potentially reduce overtreatment in patients who were misdiagnosed as LNM+.Funding: This work was supported by grants from the National Natural Science Foundation of China (Nos. 81922040, 81920108026, 81871964, 81930053, 81227901, and 81527805), the National Ten Thousand Plan Young Top Talents (for Dr. Yanlei Ma), the Shanghai Young Top Talents (for Dr. Yanlei Ma. No. QNBJ1701), the Shanghai Science and Technology Development Fund (No.19410713300), CSCO-Roche Tumor Research Fund (No. Y-2019Roche-079), the Fudan Outstanding Young Talent Training Plan (No.YJYQ201601), and the Shanghai Pujiang Program (No.17PJD007), the Beijing Natural Science Foundation under Grant No. 7182109, the National Key Research and Development Plan of China under Grant Nos. 2017YFA0205200, the Youth Innovation Promotion Association CAS (grant number 2019136). Declaration of Interest: The authors indicated no potential conflicts of interest.Ethical Approval: The study protocol complied with the Declaration of Helsinki and was approved by the ethics committee of each participating hospital.

475P Diffusion Kurtosis Imaging Signature in Predicting the Chemotherapeutic Response of Colorectal Liver Metastases: the Result of the FDZL-MRinCLM Study

104P the Value of Functional MR-imaging Signature Model for Early Prediction of Chemotherapy Response and Its Guidance for Regimen Adjustment to Improve Efficacy

Whole Tumor Based Texture Analysis of Magnetic Resonance Diffusion Imaging for Colorectal Liver Metastases: A Prospective Study for Diffusion Model Comparison and Early Response Biomarker.

A Predictive Model for Early Therapeutic Efficacy of Colorectal Liver Metastases Using Multimodal MRI Data.

Comparison of intravoxel incoherent motion imaging, diffusion kurtosis imaging, and conventional DWI in predicting the chemotherapeutic response of colorectal liver metastases

The growth pattern of liver metastases on MRI predicts early recurrence in patients with colorectal cancer: a multicenter study

Magnetic resonance imaging-radiomics evaluation of response to chemotherapy for synchronous liver metastasis of colorectal cancer

592P the Role of Early Change in Circulating Tumor DNA As a Potential Predictor of Response to Chemotherapy in Patients with Metastatic Colorectal Cancer

MR Texture Analysis: Potential Imaging Biomarker for Predicting the Chemotherapeutic Response of Patients with Colorectal Liver Metastases

An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans

Pre-operative prediction of histopathological growth patterns of colorectal cancer liver metastasis using MRI-based radiomic models

Prognostication of colorectal cancer liver metastasis by CE-based radiomics and machine learning

ASO Visual Abstract: Circulating Lipid- and Inflammation-Based Risk (CLIR) Score—A Promising New Model for Predicting Outcomes in Complete Colorectal Liver Metastases Resection

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases

Baseline hepatobiliary MRI for predicting chemotherapeutic response and prognosis in initially unresectable colorectal cancer liver metastases

Circulating Lipid- and Inflammation-Based Risk (CLIR) Score: A Promising New Model for Predicting Outcomes in Complete Colorectal Liver Metastases Resection

Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases

Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients

A Novel Radiomic Signature for Prediction of Lymph Node Metastasis in T1 Colorectal Cancer: A Multicenter Study

The multi-omics signature to predict sensitive to anti-epidermal growth factor receptor therapy in RAS wild-type colorectal cancer liver metastases.

Novel Radiomic Signature As a Prognostic Biomarker for Locally Advanced Rectal Cancer.